Related Experiment Video
Updated: Jul 8, 2026
05:53
A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
Published on: December 7, 2021
Gene therapy for adenosine deaminase deficiency.
R Parkman1, K Weinberg, G Crooks
1Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, California, USA. rparkman@chla.usc.edu
Annual Review of Medicine
|April 25, 2000
Summary
Gene therapy for adenosine deaminase (ADA) deficiency shows promise using hematopoietic stem cells (HSC). However, low transduction rates and lack of expression in non-dividing cells limit current clinical success for ADA gene therapy.
Area of Science:
- * Hematology
- * Immunology
- * Gene Therapy
Background:
- * Adenosine deaminase (ADA) deficiency is a severe genetic disorder.
- * Hematopoietic stem cell (HSC) gene therapy offers a potential treatment avenue.
- * Current trials highlight both the promise and challenges of this approach.
Purpose of the Study:
- * To evaluate the clinical outcomes of gene therapy for ADA deficiency using HSC.
- * To identify the limitations hindering the efficacy of current gene therapy strategies.
- * To outline necessary improvements for successful HSC-based gene therapy.
Main Methods:
- * Transduction of HSC from umbilical cord blood and neonatal bone marrow using retroviral vectors.
- * Engraftment assessment of transduced HSC in nonmyeloablated patients.
- * Analysis of gene expression in transduced cells, particularly T lymphocytes.
Main Results:
- * Successful transduction and engraftment of HSC were observed.
- * A low frequency of HSC transduction and engraftment (1 in 10,000) was noted.
- * Transduced ADA gene expression was absent in non-dividing T lymphocytes, despite a selective advantage for transduced T lymphoid progeny.
Conclusions:
- * Current HSC gene therapy for ADA deficiency demonstrates potential but faces significant limitations.
- * Future advancements require novel vectors capable of gene expression in non-dividing cells.
- * Increasing the efficiency of stable HSC transduction is crucial for therapeutic success.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
02:23RNA Editing
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...